should we worry?27 Nov 2021 06:31
Assuming a resurgence of Covid;
Pluses:
1. Co is funded
2. Bioprocessing collaboration with eg Pfizer, Merck will still go ahead in H1-22, may even accelerate
3. Water monitoring trials still in progress (US, UK, China, India), more demand expected if all goes well
4. Microtox BT trials ongoing, will not be delayed, should accelerate take up if successful
5. Digital Health GP will not be delayed, probably more demand and acceleration
Negatives:
1. China TDM might be delayed? Not sure, if a license is obtained by China Distributor why postpone a moneyspinner?
But yes, maybe the signing of the agreement may be delayed.
2. Share sales by Placees, wishing to lock their profit; frankly, not much to do BUT who's wiser? Someone selling at 0.15, or someone buying?
At the end of the day, the Virus will impact leisure, travel, mining, energy, cryptos, overvalued tech cos etc. BUT, why would it negatively impact a Med-Tech Co whose product/services accelerate both the detection/monitoring of Covid AND help in developing new vaccines/drugs????
DYOR - GLA